In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu dopisy, multicentrická studie, práce podpořená grantem
PubMed
31595038
DOI
10.1038/s41375-019-0591-9
PII: 10.1038/s41375-019-0591-9
Knihovny.cz E-zdroje
- MeSH
- akutní lymfatická leukemie genetika MeSH
- B-lymfocyty imunologie MeSH
- bcr-abl fúzní proteiny genetika MeSH
- chronická myeloidní leukemie genetika MeSH
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- protoonkogenní proteiny c-abl imunologie MeSH
- senioři MeSH
- věkové faktory MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- dopisy MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Názvy látek
- ABL1 protein, human MeSH Prohlížeč
- bcr-abl fúzní proteiny MeSH
- BCR-ABL1 fusion protein, human MeSH Prohlížeč
- protoonkogenní proteiny c-abl MeSH
Ancona University Ancona Italy
ASST Papa Giovanni XXIII Bergamo Italy
Cardarelli Hospital Naples Italy
Catania University Catania Italy
Children's Cancer Research Institute Wien Austria
Christian Medical College Vellore India
CHU Bordeaux Haut Léveque Bordeaux France
Department of Hematology VUMC Amsterdam The Netherlands
Department of Pathology St Jude Children's Cancer Research Hospital Memphis TN USA
ECOG ACRIN Leukemia Laboratory Montefiore Medical Center New York NY USA
Federico 2 University Naples Italy
Fundeni Clinical Institute Bucharest Romania
Hammersmith Hospital London UK
Heamatology Department of Precision and Translational Medicine Sapienza University Rome Italy
Hospital Maciel Montevideo Uruguay
Institut Pasteur Tunis Tunisie
Institute of Hematology L and A Seràgnoli Bologna University Bologna Italy
Instituto de Prevision Social Asuncion Paraguay
Islamic Azada University and Payvand Lab Tehran Iran
MLL Munich Leukemia Laboratory GmbH Munich Germany
Modena and Reggio Emilia University Modena Italy
Orbassano Hospital Turin University Turin Italy
San Raffaele University Milan Italy
St James Hospital Dublin Ireland
The Royal London Hospital London UK
Universidad Nacional de Asuncion San Lorenzo Paraguay
Universitat Leipzig Leipzig Germany
University Clinical Center Ljubljana Slovenia
University Hospital and Masaryk University Brno Czech Republic
University Hospital Center Zagreb Croatia
Zobrazit více v PubMed
Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78. DOI
Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:1043. vi DOI
Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biologic features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98:1702–10. DOI
Burmeister T, Schwartz S, Bartram CR, Gokbuget N, Hoelzer D, Thiel S. Patients’ age and BCR-ABL frequency in adult B-cell precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112:918–9. DOI
Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–84. DOI
Chereda B, Melo JV. The biology and pathogenesis of chronic myeloid leukemia. In: Hehlmann R, editor. Chronic myeloid leukemia. Switzerland: Springer International Publishing; 2016. p. 17–40. DOI
Ravandi F, O’Brien S, Cortes JE, Thomas DM, Garris R, Faderl S, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121:4158–64. DOI
Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. an international overview. Leukemia. 2019. https://doi.org/10.1038/s41375-018-0341-4 .
Hai A, Kizilbash NA, Zaidi SH, Alruwaili J, Shahzad K. Differences in structural elements of Bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia. Bioinformation. 2014;10:108–14. DOI
Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimomdo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–8. DOI
Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–8. DOI
Malagola M, Papayannidis C, Baccarani M. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives. Ann Hematol. 2016;95:681–93. DOI
Score J, Calasanz MJ, Ottman O, Pane F, Yeh RF, Sobrinho-Simoes MA, et al. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia. 2010;24:1742–50. DOI
Reckel S, Hamelin R, Georgeon S, Armand F, Jolliet Q, Chiappe D, et al. Differences in structural elements of bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia. Leukemia. 2017;31:1502–15. DOI
Cutler J, Tahir R, Sreenivasamurthy SK, Mitchell C, Renuse S, Nirujogi RS. Differential signaling through p190 and p210 BCR-ABL fusion proteins reveales by interactome and phosphoproteome analysis. Leukemia. 2017;31:1513–24. DOI
